Physician profile
William L Smith
NPI 1619221751
$1,529.09
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $259.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $336.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.37 | 2021-2022 | |
| Genzyme Corporation | $175.42 | 2021-2022 | |
| Glaxosmithkline, LLC. | $162.82 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $133.71 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.33 | 2021-2022 | |
| Pfizer INC. | $91.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $56.38 | 2021 | |
| Aimmune Therapeutics, INC. | $44.70 | 2021 | |
| Alk-Abello, INC | $38.68 | 2021 | |
| Kaleo, INC. | $35.97 | 2021-2022 | |
| Optinose US, INC. | $32.20 | 2021 | |
| Adma Biomanufacturing LLC | $24.40 | 2022 | |
| Amgen INC. | $24.33 | 2022 | |
| Horizon Therapeutics Plc | $22.10 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $18.67 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.